Literature DB >> 3698163

Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats.

R Rahmani, F Guéritte, M Martin, S Just, J P Cano, J Barbet.   

Abstract

The kinetics of distribution and elimination in rats of the antitumor drug navelbine and of two of its analogues, Na-formyl navelbine and deacetyl navelbine amide, have been studied by radioimmunoassay and compared with the kinetics obtained with vinblastine and vincristine. Fitting to two-exponential curves was used to derive pharmacokinetic parameters. Clearance was found to parallel toxicity for all drugs: it increases from 0.19 1 h-1 kg-1 for vincristine to 0.41 for Na-formyl navelbine, 1.4 for vinblastine, 2.3 for navelbine, and 2.6 for deacetyl navelbine amide. Terminal half-lives were longer for the Na-formyl-substituted alkaloids (around 13 h) than for the others (8-10 h). We have also studied navelbine kinetics in cancer patients entered in recent navelbine clinical trials and found that navelbine pharmacokinetics are characterized by fast and extensive distribution, high clearance (0.92 +/- 0.27 1 h-1 kg-1), and a relatively long terminal half-life (31.2 +/- 4.4 h). Relationships between chemical structure, pharmacokinetic properties, and toxicity or therapeutic efficiency within the Vinca alkaloid series are discussed, together with the relevance of animal models such as the rat in the screening of new antitumor drugs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3698163     DOI: 10.1007/bf00293982

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

Review 1.  Biochemistry and physiology of microtubules.

Authors:  J A Snyder; J R McIntosh
Journal:  Annu Rev Biochem       Date:  1976       Impact factor: 23.643

2.  Experimental antitumor activity of 5'-nor-anhydrovinblastine navelbine.

Authors:  R Maral; C Bourut; E Chenu; G Mathé
Journal:  Cancer Lett       Date:  1984-02       Impact factor: 8.679

3.  Conversational SAAM--an interactive program for kinetic analysis of biological systems.

Authors:  R C Boston; P C Greif; M Berman
Journal:  Comput Programs Biomed       Date:  1981 Mar-Jun

4.  Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer.

Authors:  R L Nelson; R W Dyke; M A Root
Journal:  Cancer Treat Rev       Date:  1980-09       Impact factor: 12.111

5.  A new class of antitumor compounds: 5'-nor and 5',6'-seco derivatives of vinblastine-type alkaloids.

Authors:  P Mangeney; R Z Andriamialisoa; N Langlois; Y Langlois; P Potier
Journal:  J Org Chem       Date:  1979-10-01       Impact factor: 4.354

6.  A 125I-radiolabelled probe for vinblastine and vindesine radioimmunoassays: applications to measurements of vindesine plasma levels in man after intravenous injections and long-term infusions.

Authors:  R Rahmani; J Barbet; J P Cano
Journal:  Clin Chim Acta       Date:  1983-03-28       Impact factor: 3.786

7.  Monoclonal antibodies to antitumor Vinca alkaloids: thermodynamics and kinetics.

Authors:  P A Pontarotti; R Rahmani; M Martin; J Barbet
Journal:  Mol Immunol       Date:  1985-03       Impact factor: 4.407

8.  Toxicology of vindesine (desacetyl vinblastine amide) in mice, rats, and dogs.

Authors:  G C Todd; W R Gibson; D M Morton
Journal:  J Toxicol Environ Health       Date:  1976-05

9.  Experimental in vivo cross-resistance of vinca alkaloid drugs.

Authors:  R Maral; C Bourut; E Chenu; G Mathe
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

10.  Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine).

Authors:  R Rahmani; M Martin; J Barbet; J P Cano
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

  10 in total
  14 in total

Review 1.  Clinical pharmacokinetics of vinorelbine.

Authors:  D Levêque; F Jehl
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 2.  Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.

Authors:  Monique P Curran; Greg L Plosker
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

3.  In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine.

Authors:  X J Zhou; M Martin; M Placidi; J P Cano; R Rahmani
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Oct-Dec       Impact factor: 2.441

4.  Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials.

Authors:  Laurent Nguyen; Brigitte Tranchand; Christian Puozzo; Philippe Variol
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

5.  Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients.

Authors:  T Schilling; H H Fiebig; S Kerpel-Fronius; B Winterhalter; P Variol; P Tresca; B Heinrich; A R Hanauske
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 6.  Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy.

Authors:  K L Goa; D Faulds
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

7.  Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice.

Authors:  James W Behan; Vassilios I Avramis; Jason P Yun; Stan G Louie; Steven D Mittelman
Journal:  Pharmacol Res       Date:  2010-01-18       Impact factor: 7.658

Review 8.  Preclinical and clinical pharmacology of vinca alkaloids.

Authors:  X J Zhou; R Rahmani
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 9.  The current and future place of vinorelbine in cancer therapy.

Authors:  E Cvitkovic; J Izzo
Journal:  Drugs       Date:  1992       Impact factor: 9.546

10.  Pharmacokinetics of a new anticancer drug, navelbine, in patients. Comparative study of radioimmunologic and radioactive determination methods.

Authors:  P Boré; R Rahmani; J van Cantfort; C Focan; J P Cano
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.